Efficacy, innovativeness, clinical trials, endpoints, and price of drugs with FDA approval for non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Michaeli, C. T. [1 ]
Michaeli, J. C. [2 ]
Desai, A. [3 ]
Albers, S. [4 ]
Michaeli, D. T. [5 ]
机构：
[1] UMM Univ Klinikum Mannheim, Abt Personalisierte Onkol Schwerpunkt Lungenkar, Mannheim, Germany
[2] Univ Hosp Munich, Dept Gynecol & Obstet, Breast Ctr & CCC Munich, BZKF, Munich, Germany
[3] Univ Alabama Birmingham, Div Hematol & Oncol, Dept Med, Birmingham, AL USA
[4] Tech Univ Munich, Klin & Poliklinik Unfallchirurgie, Klinikum Rechts Isar, Munich, Germany
[5] Natl Ctr Tumor Dis NCT Heidelberg, Dept Med Oncol, Heidelberg, Germany
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1386
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1331P
引用
收藏
页码：S845 / S845
页数：1
相关论文
共 50 条
  • [31] Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Cohen, Martin H.
    Johnson, John R.
    Chattopadhyay, Somesh
    Tang, Shenghui
    Justice, Robert
    Sridhara, Rajeshwari
    Pazdur, Richard
    ONCOLOGIST, 2010, 15 (12): : 1344 - 1351
  • [32] Partial orphan cancer drugs: FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending
    Michaeli, D. T.
    Michaeli, C. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S927 - S927
  • [33] Use of progression-free survival (PES) as an endpoint in advanced non-small cell lung cancer (NSCLC) trials: FDA perspective
    Malik, S. M.
    Ibrahim, A.
    Sridhara, R.
    Justice, R. L.
    Pazdur, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Evolution of statistical methodology and design of phase II/III clinical trials in non-small cell lung cancer (NSCLC).
    Bagai, R. K.
    Dowlati, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 391S - 391S
  • [35] Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?
    Clarke, Jeffrey M.
    Wang, Xiaofei
    Ready, Neal E.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (06) : 804 - 808
  • [36] The progress of tumor vaccines clinical trials in non-small cell lung cancer
    Wang, Xiaomu
    Niu, Yunping
    Bian, Fang
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (03): : 1062 - 1074
  • [37] Barriers to Enrollment in Non-small Cell Lung Cancer Therapeutic Clinical Trials
    Baggstrom, Maria Q.
    Waqar, Saiama N.
    Sezhiyan, Ananth K.
    Gilstrap, Eve
    Gao, Feng
    Morgensztern, Daniel
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (01) : 98 - 102
  • [38] Immunotherapy for non-small cell lung cancer: current concepts and clinical trials
    Mayor, Marissa
    Yang, Neng
    Sterman, Daniel
    Jones, David R.
    Adusumilli, Prasad S.
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2016, 49 (05) : 1324 - 1333
  • [39] Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials
    Yu, Le
    Yang, Ruoyi
    Long, Zeng
    Tao, Qingxiu
    Liu, Bin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [40] Non-small cell lung cancer (NSCLC) in elderly patients
    Batura-Gabryel, H.
    Brajer, B.
    LUNG CANCER, 2006, 52 : S19 - S19
12345